
|Videos|December 23, 2021
Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma
Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.
Advertisement
Episodes in this series

Advertisement
Related to this article

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Longer Follow-Up of BEHOLD-1 Shows Durable Responses With Mo-Rez in Platinum-Resistant Ovarian Cancer
3
Dr Backes on BEHOLD-1 Data With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer
4
Prizlon-Cel Nets FDA RMAT and Fast Track Designations in R/R LBCL
5

